Qiming Venture Partners and Its Investors Win Seven Awards Including Top 10 Best IPO Investment Institutions of 2025 by IPO Zao Zhi Dao
We hope to highlight investment firms that were bolder in their early-stage bets and backed projects that exerted greater influence on their industries and the market at large.
Recently, IPO Zaodao released its 2025 Top 100 IPO Investment Institutions rankings. Continuing the methodology of the past six years, the rankings do not simply tally and rank institutions by IPO count alone, but aim to highlight those firms that are bolder in early-stage investing and have backed projects with greater influence on their industries and the broader market.
Qiming Venture Partners was honored with 2025 Top 10 IPO Investment Institution, Best AI Investment Institution, Best Embodied Artificial Intelligence Investment Institution, Best Global Expansion Investment Institution, Best Healthcare Investment Institution, and Best ESG Investment Institution. Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare Innovation, was named Value Catcher of the Year.**
Qiming Venture Partners
Honored With
2025 Top 10 IPO Investment Institution
Best AI Investment Institution
Best Embodied Artificial Intelligence Investment Institution
Best Global Expansion Investment Institution
Best Healthcare Investment Institution
Best ESG Investment Institution
Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare Innovation
Honored With
Value Catcher of the Year**
Selection Criteria
The IPO Zaodao 2025 Top 100 IPO Investment Institutions list is compiled based on two data points: IPO project count and an influence index, which together produce a composite score ranked from highest to lowest. Project count carries a 70% weight, while the influence index carries 30% (on a 1–7 scale, with 7 being highest). The formula is: Composite Score = IPO Project Count × 0.7 + Influence Index × 0.3.
IPO Zaodao noted that by the numbers, IPO market activity in 2025 has recovered to 2023 levels, emerging from the "trough" of 2024. By project count, pharmaceuticals and biotech, hardware equipment, and software services were the most active sectors for IPOs. Riding the wave of AI technology, these three areas represent directions where Chinese companies are continually building strength — and where the venture capital market sees validation.
Source | IPO Zaodao
Past Coverage
Qiming Honors | Qiming Venture Partners Ranked 5th on Zero2IPO's 2024 China VC Firms List, Among 5 Awards Qiming Honors | Qiming Venture Partners and Investors Win Shanghai Securities News 2025 "Eagle·Finance" Awards Qiming Honors | Qiming Venture Partners Wins 3 Awards at China Venture Capital Research Institute's 2025 China VC Industry Golden Investment Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare Innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and others.